Newsroom

BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to ob...

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates. GCTx unveiled its initial pipeline programs focused on demyelinating neurological disorders, including multiple sclerosis (MS), and a regenerative cell therapy program for metabolic diseases, including Type 1 Diabetes. B...

PLANO, Texas--(BUSINESS WIRE)--Upbound Group, Inc. (“Upbound” or the “Company”) (NASDAQ: UPBD), a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers, today announced that Fahmi Karam, CEO, and Hal Khouri, CFO, will participate in a Fireside Chat presentation at the 2026 ICR Conference in Orlando, Florida, on Tuesday, January 13, at 3:30 PM ET. A live webcast of the presentation will be availa...

GOLDEN, Colo. & MONTREAL--(BUSINESS WIRE)--MOLSON COORS BEVERAGE COMPANY ANNOUNCES 2025 FOURTH QUARTER AND FULL YEAR EARNINGS DATE AND PARTICIPATION AT THE 2026 CAGNY CONFERENCE...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead...

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company’s plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India. The company's fireside chat will be webcast live beginning at 1:30 p.m. ET. Those wis...

COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF)....

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. “We are delighted to welcome Maria to our Board of Directors,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “She brings an exceptionally strong track record...

BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an...